Bell-Kenz Pharma

Bell-Kenz Pharma is a Philippine-based pharmaceutical company that specializes in the distribution and marketing of branded generic medicines. The company's portfolio is heavily focused on chronic disease management, particularly in cardiology, endocrinology, and nephrology. Key products include treatments for hypertension, diabetes, and dyslipidemia, such as versions of losartan, amlodipine, and metformin. Founded in 2006 by a group of Filipino medical professionals, the company aims to provide high-quality yet affordable alternatives to multinational brands. In 2024, Bell-Kenz became the center of a high-profile legislative investigation in the Philippines regarding its marketing practices and alleged incentive schemes for prescribing physicians.